| Literature DB >> 35444213 |
Min Nian1, Wei Zhou2,3, Yan Feng1, Yan Wang1,4,5, Qian Chen6, Jun Zhang7,8.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are widespread chemicals. Legacy PFAS have been phased out of production in most developed countries and emerging PFAS (short-chain PFAS and polyfluorinated compounds) are used as legacy PFAS alternatives. The effect of legacy and emerging PFAS on cytokine homeostasis in human remains poorly understood. This study aimed to evaluate the associations between legacy and emerging PFAS and cytokine profiles, and identify the main contributors to the disturbance of cytokine homeostasis. We quantified 21 PFAS in 198 Chinese women of childbearing age from 2015 to 2016. 13 cytokines were measured using the Meso Scale Discovery U-PLEX and V-PLEX platforms. The associations between PFAS exposure and cytokine levels were assessed using multiple linear regression (single-exposure), and Bayesian kernel machine regression (BKMR) models (PFAS mixture exposure). In single PFAS models, legacy and alternative PFAS were positively associated with Th1 and Treg cytokines, and negatively associated with Th2 and Th17 cytokines. For instance, each ln-unit increase in 6:2 chlorinated perfluoroalkyl ether sulfonic acid (6:2 Cl-PFESA), perfluorooctanoic acid (PFOA), and perfluorooctane sulfonate (PFOS) was associated with a decrease in IL-10 by - 0.228 (95% CI: - 0.336, - 0.120), - 0.153 (95% CI: - 0.277, - 0.030), and - 0.174 (95% CI: - 0.339, - 0.010), respectively. The BKMR model showed a significantly positive association of PFAS mixture with TGF-β and a negative association with IL-10. Overall, these results indicate that both legacy and emerging PFAS may affect the homeostasis of cytokines.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35444213 PMCID: PMC9021217 DOI: 10.1038/s41598-022-10501-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Characteristics of participants.
| Characteristic | n | Mean ± SD or % |
|---|---|---|
| Age (year) | 198 | 27.7 ± 3.5 |
| BMI (kg/m2) | 198 | 23.2 ± 3.8 |
| Age at menarche (year) | 198 | 14.2 ± 1.6 |
| Primary school | 22 | 11.1 |
| Middle school | 134 | 67.7 |
| Above middle school | 42 | 21.2 |
Distribution of plasma PFAS.
| PFAS (ng/mL) | Detection rate (%) | 25th | 50th | 75th | Mean | SD |
|---|---|---|---|---|---|---|
| n-PFHxS | 100 | 0.115 | 0.155 | 0.269 | 0.234 | 0.265 |
| Br-PFHxS | 69.7 | 0.007 | 0.012 | 0.015 | 0.014 | 0.018 |
| 6 m-PFOS | 100.0 | 0.153 | 0.238 | 0.362 | 0.317 | 0.278 |
| 1 m-PFOS | 100.0 | 0.067 | 0.104 | 0.163 | 0.131 | 0.101 |
| ∑3,4,5 m-PFOS | 100.0 | 0.254 | 0.401 | 0.924 | 0.645 | 0.566 |
| Br-PFOS | 100.0 | 0.486 | 0.752 | 1.605 | 1.093 | 0.865 |
| n-PFOS | 100.0 | 1.434 | 2.321 | 3.883 | 3.277 | 3.061 |
| 6:2 Cl-PFESA | 100.0 | 0.741 | 1.403 | 2.402 | 2.226 | 4.021 |
| 8:2 Cl-PFESA | 100.0 | 0.036 | 0.060 | 0.078 | 0.065 | 0.051 |
| HFPO-DA | 95.5 | 0.007 | 0.011 | 0.033 | 0.020 | 0.016 |
| PFBS | 80.8 | 0.011 | 0.022 | 0.049 | 0.042 | 0.056 |
| PFHpA | 96.5 | 0.029 | 0.051 | 0.101 | 0.079 | 0.105 |
| PFBA | 96.0 | 0.065 | 0.095 | 0.121 | 0.136 | 0.631 |
| PFHxA | 93.9 | 0.009 | 0.017 | 0.041 | 0.043 | 0.082 |
| PFOA | 100.0 | 2.406 | 3.938 | 7.645 | 8.566 | 14.420 |
| PFOS | 100.0 | 2.094 | 3.371 | 5.540 | 4.370 | 3.711 |
| PFNA | 100.0 | 0.315 | 0.473 | 0.739 | 0.652 | 0.571 |
| PFDA | 100.0 | 0.218 | 0.369 | 0.653 | 0.514 | 0.499 |
| PFHxS | 100.0 | 0.126 | 0.167 | 0.281 | 0.249 | 0.280 |
| PFHpS | 100.0 | 0.058 | 0.081 | 0.105 | 0.088 | 0.047 |
| PFDoA | 100.0 | 0.065 | 0.092 | 0.131 | 0.269 | 1.321 |
| PFUdA | 100.0 | 0.206 | 0.320 | 0.566 | 0.427 | 0.325 |
Serum cytokine concentrations in participants (n = 198).
| Detection rate (%) | 25th | 50th | 75th | Mean | SD | |
|---|---|---|---|---|---|---|
| IL-1β (ng/mL) | 33.8 | 0.01 | 0.02 | 0.05 | 0.06 | 0.16 |
| IL-2 (ng/mL) | 26.8 | 0.02 | 0.06 | 0.13 | 0.12 | 0.24 |
| IL-8 (ng/mL) | 100.0 | 6.1 | 8.21 | 10.89 | 14.69 | 32.35 |
| IL-12p70 (ng/mL) | 41.4 | 0.02 | 0.05 | 0.09 | 0.08 | 0.09 |
| TNF-α (ng/mL) | 100.0 | 0.91 | 1.19 | 1.54 | 1.24 | 0.47 |
| IFN-γ (ng/mL) | 100.0 | 4.21 | 6.12 | 10.49 | 10.23 | 17.50 |
| IL-4 (ng/mL) | 6.1 | 0.002 | 0.006 | 0.009 | 0.015 | 0.03 |
| IL-6 (ng/mL) | 100.0 | 0.25 | 0.40 | 0.62 | 0.50 | 0.37 |
| IL-10 (ng/mL) | 100.0 | 0.08 | 0.13 | 0.21 | 0.25 | 0.81 |
| IL-13 (ng/mL) | 27.3 | 0.10 | 0.18 | 0.46 | 0.35 | 0.54 |
| IL-17 (ng/mL) | 100.0 | 0.46 | 0.80 | 1.34 | 1.07 | 1.23 |
| IL-22 (ng/mL) | 94.4 | 0.14 | 0.31 | 0.69 | 0.97 | 3.34 |
| TGF-β (μg/mL) | 100.0 | 14.35 | 17.4 | 21.57 | 18.11 | 5.40 |
Associations between single ln-transformed PFAS and cytokines in multivariable linear regression (n = 198)*.
| PFAS | Th1 | Th2 | Th17 | Treg | |||||
|---|---|---|---|---|---|---|---|---|---|
| IL-8 | IL-12p70 | TNF-α | IFN-γ | IL-6 | IL-10 | IL-17 | IL-22 | TGF-β | |
| n-PFHxS | − 0.053 (− 0.205, 0.100) | 0.294 (− 0.072, 0.660) | 0.029 (− 0.052, 0.110) | 0.144 (− 0.027, 0.315) | 0.064 (− 0.072, 0.201) | − 0.173 (− 0.354, 0.007) | 0.025 (− 0.179, 0.229) | 0.055 (− 0.239, 0.348) | |
| Br-PFHxS | − 0.125 (− 0.315, 0.064) | 0.317 (− 0.124, 0.759) | − 0.006 (− 0.106, 0.095) | − 0.005 (− 0.219, 0.208) | − 0.083 (− 0.252, 0.086) | − 0.224 (− 0.448, 0.000) | − 0.015 (− 0.270, 0.240) | − 0.052 (− 0.427, 0.323) | 0.030 (− 0.065, 0.124) |
| 6 m-PFOS | 0.063 (− 0.068, 0.195) | − 0.018 (− 0.088, 0.052) | 0.025 (− 0.123, 0.173) | − 0.037 (− 0.155, 0.081) | − 0.150 (− 0.305, 0.006) | 0.060 (− 0.117, 0.236) | − 0.029 (− 0.277, 0.220) | 0.041 (− 0.024, 0.106) | |
| 1 m-PFOS | − 0.135 (− 0.486, 0.215) | 0.017 (− 0.062, 0.096) | 0.040 (− 0.128, 0.208) | − 0.008 (− 0.141, 0.125) | − 0.066 (− 0.244, 0.111) | − 0.054 (− 0.253, 0.145) | 0.150 (− 0.131, 0.431) | 0.013 (− 0.061, 0.087) | |
| ∑3,4,5 m-PFOS | 0.062 (− 0.050, 0.174) | 0.005 (− 0.055, 0.064) | 0.001 (− 0.125, 0.127) | − 0.006 (− 0.106, 0.095) | − 0.056 (− 0.190, 0.078) | 0.097 (− 0.054, 0.248) | − 0.004 (− 0.216, 0.209) | 0.013 (− 0.043, 0.068) | |
| Br-PFOS | 0.124 (− 0.015, 0.263) | 0.178 (− 0.153, 0.508) | 0.009 (− 0.066, 0.083) | 0.041 (− 0.116, 0.198) | − 0.024 (− 0.149, 0.101) | − 0.091 (− 0.257, 0.075) | 0.043 (− 0.145, 0.232) | 0.041 (− 0.224, 0.306) | 0.017 (− 0.053, 0.086) |
| n-PFOS | − 0.017 (− 0.142, 0.108) | 0.011 (− 0.056, 0.077) | 0.081 (− 0.059, 0.221) | − 0.058 (− 0.169, 0.053) | − | − 0.109 (− 0.281, 0.063) | − 0.063 (− 0.300, 0.173) | 0.042 (− 0.020, 0.103) | |
| 6:2 Cl-PFESA | 0.025 (− 0.069, 0.119) | 0.060 (− 0.175, 0.294) | − 0.043 (− 0.092, 0.007) | − 0.052 (− 0.158, 0.053) | − 0.023 (− 0.107, 0.061) | − | − 0.089 (− 0.217, 0.039) | − 0.008 (− 0.185, 0.169) | 0.041 (− 0.006, 0.087) |
| 8:2 Cl-PFESA | − 0.067 (− 0.251, 0.116) | − 0.052 (− 0.507, 0.403) | − 0.065 (− 0.162, 0.033) | − 0.048 (− 0.254, 0.158) | − 0.153 (− 0.315, 0.010) | − 0.196 (− 0.413, 0.021) | − | − 0.209 (− 0.555, 0.137) | 0.076 (− 0.015, 0.166) |
| HFPO-DA | 0.023 (− 0.072, 0.118) | 0.110 (− 0.106, 0.326) | 0.040 (− 0.010, 0.091) | − 0.032 (− 0.139, 0.075) | − 0.020 (− 0.105, 0.066) | − 0.034 (− 0.148, 0.079) | 0.002 (− 0.127, 0.131) | − 0.056 (− 0.235, 0.123) | 0.024 (− 0.023, 0.071) |
| PFOA | − 0.012 (− 0.117, 0.093) | 0.048 (− 0.216, 0.313) | − 0.012 (− 0.067, 0.044) | − | − 0.084 (− 0.177, 0.010) | − | 0.028 (− 0.117, 0.173) | − | |
| PFOS | 0.034 (− 0.105, 0.174) | 0.008 (− 0.066, 0.082) | 0.079 (− 0.077, 0.235) | − 0.046 (− 0.170, 0.079) | − | − 0.080 (− 0.271, 0.110) | − 0.017 (− 0.281, 0.246) | 0.044 (− 0.025, 0.113) | |
*Adjusted for age, BMI, age at menarche, and education.
Bold characters indicate significance, P < 0.05.
Figure 1Quantile g-computation regression analysis of the relationship between PFAS levels and cytokines. Models were adjusted for age, BMI, age at menarche, and education.
Figure 2Combined effects of PFAS mixture on changes in ln-cytokines were estimated by Bayesian Kernel Machine Regression (BKMR) model when all PFAS were fixed at a specific percentile compared to when all of them were fixed at the 50th percentile. Models were adjusted for age, BMI, menarche, and education.